BHC vs. HCM, XENE, IDYA, BHVN, FOLD, CRNX, JANX, RARE, PBH, and ARWR
Should you be buying Bausch Health Companies stock or one of its competitors? The main competitors of Bausch Health Companies include HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), Biohaven (BHVN), Amicus Therapeutics (FOLD), Crinetics Pharmaceuticals (CRNX), Janux Therapeutics (JANX), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical preparations" industry.
HUTCHMED (NASDAQ:HCM) and Bausch Health Companies (NYSE:BHC) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.
HUTCHMED has a net margin of 0.00% compared to HUTCHMED's net margin of -5.07%. Bausch Health Companies' return on equity of 0.00% beat HUTCHMED's return on equity.
In the previous week, Bausch Health Companies had 11 more articles in the media than HUTCHMED. MarketBeat recorded 13 mentions for Bausch Health Companies and 2 mentions for HUTCHMED. Bausch Health Companies' average media sentiment score of 0.53 beat HUTCHMED's score of -0.11 indicating that HUTCHMED is being referred to more favorably in the media.
HUTCHMED has higher earnings, but lower revenue than Bausch Health Companies.
8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 8.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
HUTCHMED currently has a consensus target price of $29.70, suggesting a potential upside of 52.54%. Bausch Health Companies has a consensus target price of $11.33, suggesting a potential upside of 61.33%. Given HUTCHMED's higher probable upside, analysts clearly believe Bausch Health Companies is more favorable than HUTCHMED.
HUTCHMED has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
Bausch Health Companies received 37 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.74% of users gave HUTCHMED an outperform vote while only 61.84% of users gave Bausch Health Companies an outperform vote.
Summary
HUTCHMED and Bausch Health Companies tied by winning 8 of the 16 factors compared between the two stocks.
Get Bausch Health Companies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch Health Companies Competitors List
Related Companies and Tools
